NCT05192304

Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia

A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Multiple Doses of TPN672 Tablets Maleate in Patients With Schizophrenia

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 62 (estimated)
• Sponsor: Jiangsu Kanion Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase Ib clinical study of TPN672 maleate in patients with schizophrenia

Detailed description

This is a single-center, randomized, double-blind, placebo-controlled, dosion-increasing, Phase Ib clinical study evaluating the safety, tolerability, and pharmacokinetic characteristics of multiple doses of TPN672 maleate in patients with schizophrenia

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	TPN-672	single dose of TPN-672 maleate tablet

Timeline

• Start date: 2022-02-01
• Primary completion: 2023-03-01
• Completion: 2024-03-01
• First posted: 2022-01-14
• Last updated: 2022-01-14

Locations

1 site across 1 country: China